TW200626133A - Oral medication for twice-daily administration - Google Patents
Oral medication for twice-daily administrationInfo
- Publication number
- TW200626133A TW200626133A TW094147075A TW94147075A TW200626133A TW 200626133 A TW200626133 A TW 200626133A TW 094147075 A TW094147075 A TW 094147075A TW 94147075 A TW94147075 A TW 94147075A TW 200626133 A TW200626133 A TW 200626133A
- Authority
- TW
- Taiwan
- Prior art keywords
- twice
- daily administration
- oral medication
- cysteine
- salt
- Prior art date
Links
Abstract
The invention provides an oral medication for twice-daily administration, which includes L-cysteine and ascorbic acid resistant preparation for pigmentation treatments of seborrheic keratosis, freckles, suntan, and macula. The twice-daily administration contains L-cysteine or salt thereof and ascorbic acid resistant or salt thereof, in which once dosage of L-cysteine is 90 mg to 150 mg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005014103A JP5576006B2 (en) | 2005-01-21 | 2005-01-21 | Oral dosage form twice a day |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200626133A true TW200626133A (en) | 2006-08-01 |
TWI405569B TWI405569B (en) | 2013-08-21 |
Family
ID=36957958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094147075A TWI405569B (en) | 2005-01-21 | 2005-12-28 | Oral formulation for the treatment of pigmentation symptoms in twice-daily administration |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP5576006B2 (en) |
KR (1) | KR20060085173A (en) |
CN (1) | CN1839826B (en) |
HK (1) | HK1092734A1 (en) |
TW (1) | TWI405569B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5733930B2 (en) * | 2009-09-09 | 2015-06-10 | 武田薬品工業株式会社 | Solid preparation |
KR101237498B1 (en) * | 2010-10-20 | 2013-02-26 | 주식회사 동구제약 | Pharmaceutical composition containing ascorbic acid and tranexamic acid having enhanced stability |
CN108451914A (en) * | 2018-05-31 | 2018-08-28 | 南京中生生物科技有限公司 | A kind of vitamin C oral disintegration tablet |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004026786A (en) * | 2002-05-10 | 2004-01-29 | Takeda Chem Ind Ltd | Vitamin preparation |
DE60332163D1 (en) * | 2002-12-27 | 2010-05-27 | Daiichi Sankyo Healthcare Co | COMPOSITION FOR SKIN TREATMENT |
-
2005
- 2005-01-21 JP JP2005014103A patent/JP5576006B2/en active Active
- 2005-12-28 TW TW094147075A patent/TWI405569B/en active
-
2006
- 2006-01-10 KR KR1020060002745A patent/KR20060085173A/en not_active Application Discontinuation
- 2006-01-20 CN CN2006100016471A patent/CN1839826B/en active Active
- 2006-12-19 HK HK06113974.7A patent/HK1092734A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1839826B (en) | 2012-11-07 |
HK1092734A1 (en) | 2007-02-16 |
TWI405569B (en) | 2013-08-21 |
JP2006199640A (en) | 2006-08-03 |
JP5576006B2 (en) | 2014-08-20 |
CN1839826A (en) | 2006-10-04 |
KR20060085173A (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300889I2 (en) | Trifluridine in combination with tipiracil hydrochloride | |
EA201492010A1 (en) | APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS | |
NZ604662A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine | |
MX2012000275A (en) | Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement. | |
WO2007056264A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally | |
WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
NZ605841A (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine | |
PT2210605T (en) | Once daily dosage forms of trospium | |
TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
WO2007056263A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously | |
NO20080244L (en) | Dosage control for prasugrel | |
WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
AR061233A1 (en) | FORMULATION OF PROLONGED LIBERATION OF NALTREXONA | |
MX341660B (en) | Ghrelin receptor agonist for treatment of dyscrasia. | |
TW200626133A (en) | Oral medication for twice-daily administration | |
IL173822A0 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
SE0000698D0 (en) | Use of a composition | |
NZ602032A (en) | Oral b12 therapy | |
MX2010006310A (en) | O-desmethyl-venlafaxine for treating major depressive disorder. | |
DK2091520T3 (en) | ORAL DOSAGE FORM CONTAINING TRISUBSTITUTED GLYCEROL COMPOUNDS | |
WO2007144889A3 (en) | Treatment of neurofibromatosis | |
TW200633722A (en) | Complexes made using low solubility drugs | |
NZ726636A (en) | Novel compounds and compositions for targeting cancer stem cells | |
TW200515912A (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep |